Business Wire

Samsung’s New Mid-power LED Integrates Unsurpassed Light Efficacy with Outstanding Color Quality

Share

Samsung Electronics Co., Ltd., a world leader in advanced digital component solutions, today introduced the LM301B EVO, a new mid-power LED package that has been designed to set the pace in light efficacy and color quality for indoor and industrial applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210527005376/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Samsung’s new mid-power LED integrates unsurpassed light efficacy with outstanding color quality (Photo: Business Wire)

Global regulations and standards for lighting, once centered on light efficacy, are becoming more comprehensive to include strict criteria for energy efficiency and color quality. The European Union’s energy labels for light sources (Energy-related Products Directive; ErP) have been revised to become more stringent, and the Design Lights Consortium (DLC) — a non-profit organization for lighting standards in the U.S. and Canada — has added an index for color quality while requiring the same high efficacy level.

The LM301B EVO helps to meet the rigorous lighting standards on both energy efficiency and color quality. Built upon Samsung’s proprietary flip-chip design, the LED package features the industry’s highest efficacy of 235 lumens per watt (lm/W), by applying a new reflective material inside the packaging mold and improving phosphor conversion efficiency. Samsung also fine-tuned the red spectrum in the LED’s phosphor mix to enable superior color quality, especially with the red hues which are usually more difficult to render accurately.

“Our new LM301B EVO offers an unrivaled mix of light efficacy and color rendering that aligns nicely with the changing landscape of LED lighting standards,” said Un Soo Kim, senior vice president of the LED Business Team at Samsung Electronics. “Samsung will continue to provide value-added LED light sources through technological innovation, as we push hard to exceed energy standards across the globe.”

When using the package, luminaire manufacturers can create lamps that qualify for the ErP Directive’s Grade A certification and meet the DLC’s latest V5.1 Premium requirements while achieving industry-leading efficacy.

Based on the industry-standard 3030 platform, the LM301B EVO can be easily integrated into existing and newly designed fixtures for general and premium luminaires.

The LM301B EVO is now in production and available in color temperatures ranging from 2,700K to 6,500K. To facilitate adoption into existing markets, the package will also be available in two lighting modules — the Q-series EVO optimized for indoor lighting at offices and schools, and the H inFlux EVO for high–ceiling applications including factories and warehouses.

About Samsung Electronics Co., Ltd .

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: sseg.comm@samsung.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

 Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 10:01:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 10:00:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 12:53:00 EEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Slots Capital on useampien pelaajien ulottuvilla kuin koskaan aiemmin11.6.2021 12:23:00 EEST | Tiedote

Slots Capital on yksi maailman suosituimmista nettikasinoista. Nyt se on useampien pelaajien ulottuvilla kuin koskaan aiemmin, kun sivusto on ensimmäistä kertaa käynnistänyt toimintansa useissa uusissa maissa. Tämä tarkoittaa, että pelaajat Belgiassa, Romaniassa, Kreikassa, Tanskassa, Suomessa, Irlannissa, Latviassa ja Luxemburgissa voivat nyt nauttia Slots Capitalin huippuluokan nettikasinokokemuksesta. Jos rakastat kolikkopelien pelaamista, Slots Capital on todellakin sinua varten tarjoten yli 300 peliä isoilta pelinkehittäjiltä, kuten Rival, Saucify, Dragon ja Qora. Itse asiassa lisäsimme hiljattain kolikko- ja pöytäpeliaulaamme pelejä suosituilta studioilta, kuten Rival Gamingilta, Dragon Gamingilta, Saucify Gamingilta ja Qora Gamingilta. Lisäämme pelejä myös Arrow's Edgelta tulevina viikkoina, mutta sillä välin pelaajat voivat kokeilla peliaulamme uusimpia pelejä kuten: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wr

Slots Capital Available to More Players Than Ever Before11.6.2021 12:21:00 EEST | Press release

Slots Capital, one of the most popular online casinos in the world, in now available to more players than ever before after launching into several new countries for the very first time. This means players in Belgium, Romania, Greece, Denmark, Finland, Ireland, Latvia and Luxembourg can now enjoy the top-rated online casino experience offered at Slots Capital. If you love playing slots, then Slots Capital really is the place to be. In fact, we recently boosted our slots and table games lobby with titles from in-demand studios including Rival Gaming, Dragon Gaming, Saucify Gaming and Qora Gaming. We will also be adding slots from Arrow’s Edge in the coming weeks but in the meantime, players can try the latest titles to hit our lobby including: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wrath of Medusa Yeti Hunt i3D Slots Capital is not only known for being the number one destination for slots, players also love our daily

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 11:15:00 EEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 10:18:00 EEST | Press release

Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom